PET/CT imaging as a measure of response in patients with advanced melanoma on immunotherapy plus hydroxychloroquine.

Brief description of study

The research study is a companion trial to the LIMIT Melanoma Trial, This study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on participants with advanced melanoma who are participating in the LIMIT Melanoma Trial. The imaging agent could help the doctor see where your CD8 T cells are located, which may help patients to determine likely response to treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
melanoma
Age: Between 18 Years - 99 Years
Gender: All

Male or Female, Age 18 or older History of histologically confirmed melanoma as assessed per medical record review

Updated on 09 Mar 2024. Study ID: 844867

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).